DOCSLIB.ORG

Expression Il2 Differentiation by Promoting TNFR2 Impairs Th17

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Transmembrane TNF−TNFR2 Impairs Th17 Differentiation by Promoting Il2 Expression Patrick G. Miller, Michael B. Bonn and Susan C. McKarns This information is current as J Immunol 2015; 195:2633-2647; Prepublished online 12 of October 3, 2021. August 2015; doi: 10.4049/jimmunol.1500286 http://www.jimmunol.org/content/195/6/2633 Downloaded from References This article cites 76 articles, 37 of which you can access for free at: http://www.jimmunol.org/content/195/6/2633.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on October 3, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2015 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Transmembrane TNF–TNFR2 Impairs Th17 Differentiation by Promoting Il2 Expression Patrick G. Miller,* Michael B. Bonn,* and Susan C. McKarns*,† The double-edged sword nature by which IL-2 regulates autoimmunity and the unpredictable outcomes of anti-TNF therapy in autoimmunity highlight the importance for understanding how TNF regulates IL-2. Transmembrane TNF (tmTNF) preferentially binds TNFR2, whereas soluble TNF (sTNF) binds TNFR1. We previously showed reduced IL-2 production in TNFR12/2 TNFR22/2 CD4+ T cells. In this study, we generated TNFR12/2, TNFR22/2, or TNFR12/2 TNFR22/2 5C.C7 TCR Il2-GFP mice and report that CD4+ T cell–intrinsic tmTNF/TNFR2 stimulates Il2 promoter activity and Il2 mRNA stability. We further used tmTNF Foxp3 gfp reporter mice and pharmacological TNF blockade in wild-type mice to report a tmTNF/TNFR2 interac- tion for Il2 expression. IL-17 is critical for host defense, but its overabundance promotes autoimmunity. IL-2 represses Th17 differentiation, but the role for TNFR2 in this process is not well understood. We report elevated expression of TNFR2 under Th17-polarization conditions. Genetic loss-of-function experimental models, as well as selective TNF blockade by etanercept and Downloaded from XPro1595 in wild-type mice, demonstrate that impaired tmTNF/TNFR2, but not sTNF/TNFR1, promotes Th17 differentiation in vivo and in vitro. Under Th17-polarizing conditions, elevated IL-17 production by TNFR2-knockout CD4+ T cells was asso- ciated with increased STAT3 activity and decreased STAT5 activity. Increased IL-17 production in TNFR2-knockout T cells was prevented by adding exogenous IL-2. We conclude that CD4+ T cell–intrinsic tmTNF/TNFR2 promotes IL-2 production that inhibits the generation of Th17 cells in a Foxp3-independent manner. Moreover, under Th17-polarizing conditions, selective blockade of CD4+ T cell–intrinsic TNFR2 appears to be sufficient to promote Th17 differentiation. The Journal of Immunology, http://www.jimmunol.org/ 2015, 195: 2633–2647. nterleukin-2 is essential for tolerance against self-Ags, as il- IL-2 that are produced impact the outcome of immune responses. lustrated by the autoimmune phenotype of the IL-2 knockout In naive cells, the Il2 promoter is silent, but an integrated assembly I (KO) mouse (1–3). IL-2 is produced mainly by activated CD4+ of chromatin-remodeling complexes, histone modifications, and T cells. This pleotropic cytokine signals through intermediate transcription factors, including AP-1, NF-kB, NFAT, and OCT-1, 29 affinity (KD ∼ 10 M) CD122 (IL-2Rb)/CD132 (gc) and ligand- facilitate a rapid and transient onset of Il2 promoter activity. Il2 211 specific high-affinity (KD ∼ 10 M) CD122/CD132/CD25 (IL- expression is controlled by the strength and duration of TCR sig- by guest on October 3, 2021 2Ra) receptor complexes that respond to ∼1 nM and ∼10 pM doses naling, costimulation, and rapid Il2 mRNA degradation (8, 10, 11). of IL-2, respectively (4), to activate downstream STAT5, MAPK, The CD28 response element, located 2164 to 2152 bp immedi- and PI3K signaling cascades (5). Consumption of IL-2 in the pe- ately upstream of the transcriptional start site, is especially impor- riphery by CD4+ effector T cells or regulatory T cells (Tregs) con- tant for Il2 gene transcription and posttranscriptional regulation tributes to the control of Th cell differentiation and suppressor Treg of Il2 mRNA stability. function, respectively (6–9). Given the dichotomous role of IL-2 Our knowledge of how different ligand–receptor interactions on immune regulation and the nature by which multiple cell pop- contribute to T cell activation and differentiation has steadily ulations compete for a common pool of IL-2, the rate and amount of grown to include a host of costimulatory molecules. In addition to signal 1 through the TCR and signal 2 (costimulation), we (12) and other investigators (13, 14) have shown that TNFRs promote IL-2 *Laboratory of TGF-b Biology, Epigenetics, and Cytokine Regulation, Center for Cellular and Molecular Immunology, Department of Surgery, University of Missouri production. TNF, similar to other TNF family members (e.g., LIGHT, School of Medicine, Columbia, MO 65212; and †Department of Molecular Micro- FasL, and TRAIL), exists in membrane-bound and soluble forms. biology and Immunology, University of Missouri School of Medicine, Columbia, MO The matrix metalloprotease TNF-converting enzyme cleaves trans- 65212 membrane TNF (tmTNF) from the cell surface to generate a 17-kDa Received for publication February 6, 2015. Accepted for publication July 14, 2015. soluble TNF (sTNF) (15). sTNF and tmTNF preferentially signal This work was supported by National Institutes of Health Grant R01 ES022966 and a University of Missouri Richard Wallace Faculty Incentive Grant Award (both to through TNFR1 (CD120a, p55) and TNFR2 (CD120b, p75), re- S.C.M.). spectively (16, 17). In contrast to the ubiquitous expression of Address correspondence and reprint requests to Dr. Susan C. McKarns, Department TNFR1, TNFR2 is restricted mostly to hematopoietic cells, endo- of Surgery, University of Missouri School of Medicine, M616 Medical Sciences thelium, microglia, and oligodendrocytes. Signaling downstream Building, Columbia, MO 65212. E-mail address: [email protected] of TNFR1 and TNFR2 is distinct, yet overlapping, and is mediated Abbreviations used in this article: 7-AAD, 7-aminoactinomycin D; AHR, aryl hydro- by the recruitment of adaptor proteins and the activation of down- carbon receptor; ARNT, AHR nuclear translocator; cRPMI, complete RPMI; CsA, cyclosporin A; CT, cycle threshold; dKO, double knockout; DN-TNF, dominant- stream transcription factors, including NF-kBandJNK.Incontrast negative TNF; KO, knockout; LAP, latency-associated peptide; LN, lymph node; LT, to TNFR2, TNFR1 contains an intracellular death domain and lymphotoxin; MCC, moth cytochrome c; MFI, mean fluorescence intensity; MLN, mesenteric LN; MOG, myelin oligodendrocyte glycoprotein; pY, tyrosine phosphor- promotes caspase-mediated apoptosis (18, 19). TNFR2 contains ylation; qRT-PCR, quantitative RT-PCR; ROR, retinoic acid–related orphan receptor; intracellular TNFR-associated factor binding domains. We pre- SPLN, spleen; sTNF, soluble TNF; Tg, transgenic; tmTNF, transmembrane TNF; Treg, viously associated TNFR1/TNFR2 double deficiency with im- regulatory T cell; UTR, untranslated region; WT, wild type. paired IL-2 production (20), but the individual contribution of Copyright Ó 2015 by The American Association of Immunologists, Inc. 0022-1767/15/$25.00 each of these receptors remains undefined. www.jimmunol.org/cgi/doi/10.4049/jimmunol.1500286 2634 TNFR2 REGULATES IL-2 TO CONTROL IL-17 Following activation, CD4+ T cells differentiate into distinct Abs and reagents effector subpopulations characterized by unique cytokines, tran- + TCRVb11 (KT11), CD120a (55R-286), CD120b (TR75-89), CD26 (H194- scription factors, and immune-regulatory properties. CD4 Th17 112), CD278 (C398.4A), and CD62L (MEL-14) were purchased from Bio- T cells are characterized by the expression of retinoic acid–related Legend (San Diego, CA). TCRb (H57-597), CD4 (RM4-5), CD4 (GK1.5), orphan receptor (ROR)-gt and the production of two related CD8a (Ly-2), CD120a (55R-286), CD69 (H1.2F3), CD25 (PC61), TNF effector cytokines, IL-17 and IL-17F. Th17 cells are essential (MP6-XT22), CD45Rb (16A), and CD16/CD32 (2.4 G2) were purchased from BD Biosciences (San Jose, CA). Foxp3 (FJK-16s), CD28 (37.51), and for host protection against bacterial and fungal infections, but latency-associated peptide (LAP; TW7-16B4) were purchased from eBio- too much IL-17 can promote inflammation or autoimmunity (21). science (San Diego, CA). Annexin V and 7-aminoactinomycin D (7-AAD) How TNF regulates Th17 cells is poorly understood. Given the were purchased from BD Biosciences. Lyophilized recombinant mouse 77 233 recent interest in selective activation of TNFR2 as a therapeutic TNF (aa Val –Leu , expressed in Escherichia coli) was purchased from R&D Systems (Minneapolis, MN) as a lyophilized powder, 0.2 mm filtered target, a better understanding of the selective roles of TNFR1 and 2 + in PBS without a carrier protein, stored at 80˚C, and reconstituted in TNFR2 on cytokine production by CD4 T cells is needed. The sterile PBS with 0.01% BSA (Fraction V; Sigma-Aldrich, St. Louis, MO) objective of this study was three-fold: to determine the individual as a carrier protein just prior to use. MCC aa 88–103 and myelin oligo- contribution of TNFR1 and TNFR2 to IL-2 expression, to deter- dendrocyte glycoprotein (MOG) aa 35–55 were purchased from AnaSpec minewhetherregulationofIL-2expressionbyTNFR1orTNFR2 (Fremont, CA). PMA, ionomycin, and cyclosporin A (CsA) were pur- + + chased from Calbiochem-EMD Millipore (Dormstadt, Germany).
Recommended publications
  • Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse

    Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse

    Welcome to More Choice CD Marker Handbook For more information, please visit: Human bdbiosciences.com/eu/go/humancdmarkers Mouse bdbiosciences.com/eu/go/mousecdmarkers Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse CD3 CD3 CD (cluster of differentiation) molecules are cell surface markers T Cell CD4 CD4 useful for the identification and characterization of leukocytes. The CD CD8 CD8 nomenclature was developed and is maintained through the HLDA (Human Leukocyte Differentiation Antigens) workshop started in 1982. CD45R/B220 CD19 CD19 The goal is to provide standardization of monoclonal antibodies to B Cell CD20 CD22 (B cell activation marker) human antigens across laboratories. To characterize or “workshop” the antibodies, multiple laboratories carry out blind analyses of antibodies. These results independently validate antibody specificity. CD11c CD11c Dendritic Cell CD123 CD123 While the CD nomenclature has been developed for use with human antigens, it is applied to corresponding mouse antigens as well as antigens from other species. However, the mouse and other species NK Cell CD56 CD335 (NKp46) antibodies are not tested by HLDA. Human CD markers were reviewed by the HLDA. New CD markers Stem Cell/ CD34 CD34 were established at the HLDA9 meeting held in Barcelona in 2010. For Precursor hematopoetic stem cell only hematopoetic stem cell only additional information and CD markers please visit www.hcdm.org. Macrophage/ CD14 CD11b/ Mac-1 Monocyte CD33 Ly-71 (F4/80) CD66b Granulocyte CD66b Gr-1/Ly6G Ly6C CD41 CD41 CD61 (Integrin b3) CD61 Platelet CD9 CD62 CD62P (activated platelets) CD235a CD235a Erythrocyte Ter-119 CD146 MECA-32 CD106 CD146 Endothelial Cell CD31 CD62E (activated endothelial cells) Epithelial Cell CD236 CD326 (EPCAM1) For Research Use Only.
  • LAG-3-Expressing Tumor-Infiltrating T Cells Are Associated with Reduced

    LAG-3-Expressing Tumor-Infiltrating T Cells Are Associated with Reduced

    cancers Article LAG-3-Expressing Tumor-Infiltrating T Cells Are Associated with Reduced Disease-Free Survival in Pancreatic Cancer Lena Seifert 1,2,3,†, Ioana Plesca 4,†, Luise Müller 4, Ulrich Sommer 5, Max Heiduk 1,2, Janusz von Renesse 1, David Digomann 1, Jessica Glück 1, Anna Klimova 6,7, Jürgen Weitz 1,2,3, Marc Schmitz 2,3,4 and Adrian M. Seifert 1,2,3,* 1 Department of Visceral, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus, TU Dresden, 01307 Dresden, Germany; [email protected] (L.S.); [email protected] (M.H.); [email protected] (J.v.R.); [email protected] (D.D.); [email protected] (J.G.); [email protected] (J.W.) 2 National Center for Tumor Diseases (NCT), Partner Site Dresden, 69120 Heidelberg, Germany; [email protected] 3 German Cancer Consortium (DKTK), Partner Site Dresden, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany 4 Faculty of Medicine Carl Gustav Carus, Institute of Immunology, TU Dresden, 01307 Dresden, Germany; [email protected] (I.P.); [email protected] (L.M.) 5 Faculty of Medicine Carl Gustav Carus, Institute of Pathology, TU Dresden, 01307 Dresden, Germany; [email protected] 6 Faculty of Medicine Carl Gustav Carus, Institute for Medical Informatics and Biometry, TU Dresden, 01307 Dresden, Germany; [email protected] 7 National Center for Tumor Diseases (NCT), Core Unit for Data Management and Analytics (CDMA), Citation: Seifert, L.; Plesca, I.; Müller, 01307 Dresden, Germany L.; Sommer, U.; Heiduk, M.; von * Correspondence: [email protected] Renesse, J.; Digomann, D.; Glück, J.; † These authors have contributed equally to this work.
  • Effector CD4 T-Cell Transition to Memory Requires Late Cognate Interactions That Induce Autocrine IL-2

    Effector CD4 T-Cell Transition to Memory Requires Late Cognate Interactions That Induce Autocrine IL-2

    ARTICLE Received 3 Jun 2014 | Accepted 24 Sep 2014 | Published 5 Nov 2014 DOI: 10.1038/ncomms6377 Effector CD4 T-cell transition to memory requires late cognate interactions that induce autocrine IL-2 K. Kai McKinstry1,*, Tara M. Strutt1,*, Bianca Bautista1, Wenliang Zhang1, Yi Kuang1, Andrea M. Cooper2 & Susan L. Swain1 It is unclear how CD4 T-cell memory formation is regulated following pathogen challenge, and when critical mechanisms act to determine effector T-cell fate. Here, we report that following influenza infection most effectors require signals from major histocompatibility complex class II molecules and CD70 during a late window well after initial priming to become memory. During this timeframe, effector cells must produce IL-2 or be exposed to high levels of paracrine or exogenously added IL-2 to survive an otherwise rapid default contraction phase. Late IL-2 promotes survival through acute downregulation of apoptotic pathways in effector T cells and by permanently upregulating their IL-7 receptor expression, enabling IL-7 to sustain them as memory T cells. This new paradigm defines a late checkpoint during the effector phase at which cognate interactions direct CD4 T-cell memory generation. 1 Department of Pathology, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, Massachusetts 01655, USA. 2 Trudeau Institute, 154 Algonquin Avenue, Saranac Lake, New York 12983, USA. * These authors contributed equally to this work. Correspondence and requests for materials should be addressed to K.K.M. (email: [email protected]). NATURE COMMUNICATIONS | 5:5377 | DOI: 10.1038/ncomms6377 | www.nature.com/naturecommunications 1 & 2014 Macmillan Publishers Limited.
  • TNF Decoy Receptors Encoded by Poxviruses

    TNF Decoy Receptors Encoded by Poxviruses

    pathogens Review TNF Decoy Receptors Encoded by Poxviruses Francisco Javier Alvarez-de Miranda † , Isabel Alonso-Sánchez † , Antonio Alcamí and Bruno Hernaez * Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas, Campus de Cantoblanco, Universidad Autónoma de Madrid, Nicolás Cabrera 1, 28049 Madrid, Spain; [email protected] (F.J.A.-d.M.); [email protected] (I.A.-S.); [email protected] (A.A.) * Correspondence: [email protected]; Tel.: +34-911-196-4590 † These authors contributed equally. Abstract: Tumour necrosis factor (TNF) is an inflammatory cytokine produced in response to viral infections that promotes the recruitment and activation of leukocytes to sites of infection. This TNF- based host response is essential to limit virus spreading, thus poxviruses have evolutionarily adopted diverse molecular mechanisms to counteract TNF antiviral action. These include the expression of poxvirus-encoded soluble receptors or proteins able to bind and neutralize TNF and other members of the TNF ligand superfamily, acting as decoy receptors. This article reviews in detail the various TNF decoy receptors identified to date in the genomes from different poxvirus species, with a special focus on their impact on poxvirus pathogenesis and their potential use as therapeutic molecules. Keywords: poxvirus; immune evasion; tumour necrosis factor; tumour necrosis factor receptors; lymphotoxin; inflammation; cytokines; secreted decoy receptors; vaccinia virus; ectromelia virus; cowpox virus Citation: Alvarez-de Miranda, F.J.; Alonso-Sánchez, I.; Alcamí, A.; 1. TNF Biology Hernaez, B. TNF Decoy Receptors TNF is a potent pro-inflammatory cytokine with a broad range of biological effects, Encoded by Poxviruses. Pathogens ranging from the activation of inflammatory gene programs to cell differentiation or 2021, 10, 1065.
  • Dimerization of Ltβr by Ltα1β2 Is Necessary and Sufficient for Signal

    Dimerization of Ltβr by Ltα1β2 Is Necessary and Sufficient for Signal

    Dimerization of LTβRbyLTα1β2 is necessary and sufficient for signal transduction Jawahar Sudhamsua,1, JianPing Yina,1, Eugene Y. Chiangb, Melissa A. Starovasnika, Jane L. Groganb,2, and Sarah G. Hymowitza,2 Departments of aStructural Biology and bImmunology, Genentech, Inc., South San Francisco, CA 94080 Edited by K. Christopher Garcia, Stanford University, Stanford, CA, and approved October 24, 2013 (received for review June 6, 2013) Homotrimeric TNF superfamily ligands signal by inducing trimers survival in a xenogeneic human T-cell–dependent mouse model of of their cognate receptors. As a biologically active heterotrimer, graft-versus-host disease (GVHD) (11). Lymphotoxin(LT)α1β2 is unique in the TNF superfamily. How the TNFRSF members are typically activated by TNFSF-induced three unique potential receptor-binding interfaces in LTα1β2 trig- trimerization or higher order oligomerization, resulting in initiation ger signaling via LTβ Receptor (LTβR) resulting in lymphoid organ- of intracellular signaling processes including the canonical and ogenesis and propagation of inflammatory signals is poorly noncanonical NF-κB pathways (2, 3). Ligand–receptor interactions α β understood. Here we show that LT 1 2 possesses two binding induce higher order assemblies formed between adaptor motifs in sites for LTβR with distinct affinities and that dimerization of LTβR the cytoplasmic regions of the receptors such as death domains or α β fi by LT 1 2 is necessary and suf cient for signal transduction. The TRAF-binding motifs and downstream signaling components such α β β crystal structure of a complex formed by LT 1 2,LT R, and the fab as Fas-associated protein with death domain (FADD), TNFR1- fragment of an antibody that blocks LTβR activation reveals the associated protein with death domain (TRADD), and TNFR-as- lower affinity receptor-binding site.
  • The Unexpected Role of Lymphotoxin Β Receptor Signaling

    The Unexpected Role of Lymphotoxin Β Receptor Signaling

    Oncogene (2010) 29, 5006–5018 & 2010 Macmillan Publishers Limited All rights reserved 0950-9232/10 www.nature.com/onc REVIEW The unexpected role of lymphotoxin b receptor signaling in carcinogenesis: from lymphoid tissue formation to liver and prostate cancer development MJ Wolf1, GM Seleznik1, N Zeller1,3 and M Heikenwalder1,2 1Department of Pathology, Institute of Neuropathology, University Hospital Zurich, Zurich, Switzerland and 2Institute of Virology, Technische Universita¨tMu¨nchen/Helmholtz Zentrum Mu¨nchen, Munich, Germany The cytokines lymphotoxin (LT) a, b and their receptor genesis. Consequently, the inflammatory microenviron- (LTbR) belong to the tumor necrosis factor (TNF) super- ment was added as the seventh hallmark of cancer family, whose founder—TNFa—was initially discovered (Hanahan and Weinberg, 2000; Colotta et al., 2009). due to its tumor necrotizing activity. LTbR signaling This was ultimately the result of more than 100 years of serves pleiotropic functions including the control of research—indeed—the first observation that tumors lymphoid organ development, support of efficient immune often arise at sites of inflammation was initially reported responses against pathogens due to maintenance of intact in the nineteenth century by Virchow (Balkwill and lymphoid structures, induction of tertiary lymphoid organs, Mantovani, 2001). Today, understanding the underlying liver regeneration or control of lipid homeostasis. Signal- mechanisms of why immune cells can be pro- or anti- ing through LTbR comprises the noncanonical/canonical carcinogenic in different types of tumors and which nuclear factor-jB (NF-jB) pathways thus inducing cellular and molecular inflammatory mediators (for chemokine, cytokine or adhesion molecule expression, cell example, macrophages, lymphocytes, chemokines or proliferation and cell survival.
  • CD Markers Are Routinely Used for the Immunophenotyping of Cells

    CD Markers Are Routinely Used for the Immunophenotyping of Cells

    ptglab.com 1 CD MARKER ANTIBODIES www.ptglab.com Introduction The cluster of differentiation (abbreviated as CD) is a protocol used for the identification and investigation of cell surface molecules. So-called CD markers are routinely used for the immunophenotyping of cells. Despite this use, they are not limited to roles in the immune system and perform a variety of roles in cell differentiation, adhesion, migration, blood clotting, gamete fertilization, amino acid transport and apoptosis, among many others. As such, Proteintech’s mini catalog featuring its antibodies targeting CD markers is applicable to a wide range of research disciplines. PRODUCT FOCUS PECAM1 Platelet endothelial cell adhesion of blood vessels – making up a large portion molecule-1 (PECAM1), also known as cluster of its intracellular junctions. PECAM-1 is also CD Number of differentiation 31 (CD31), is a member of present on the surface of hematopoietic the immunoglobulin gene superfamily of cell cells and immune cells including platelets, CD31 adhesion molecules. It is highly expressed monocytes, neutrophils, natural killer cells, on the surface of the endothelium – the thin megakaryocytes and some types of T-cell. Catalog Number layer of endothelial cells lining the interior 11256-1-AP Type Rabbit Polyclonal Applications ELISA, FC, IF, IHC, IP, WB 16 Publications Immunohistochemical of paraffin-embedded Figure 1: Immunofluorescence staining human hepatocirrhosis using PECAM1, CD31 of PECAM1 (11256-1-AP), Alexa 488 goat antibody (11265-1-AP) at a dilution of 1:50 anti-rabbit (green), and smooth muscle KD/KO Validated (40x objective). alpha-actin (red), courtesy of Nicola Smart. PECAM1: Customer Testimonial Nicola Smart, a cardiovascular researcher “As you can see [the immunostaining] is and a group leader at the University of extremely clean and specific [and] displays Oxford, has said of the PECAM1 antibody strong intercellular junction expression, (11265-1-AP) that it “worked beautifully as expected for a cell adhesion molecule.” on every occasion I’ve tried it.” Proteintech thanks Dr.
  • Human Peripheral Blood Gamma Delta T Cells: Report on a Series of Healthy Caucasian Portuguese Adults and Comprehensive Review of the Literature

    Human Peripheral Blood Gamma Delta T Cells: Report on a Series of Healthy Caucasian Portuguese Adults and Comprehensive Review of the Literature

    cells Article Human Peripheral Blood Gamma Delta T Cells: Report on a Series of Healthy Caucasian Portuguese Adults and Comprehensive Review of the Literature 1, 2, 1, 1, Sónia Fonseca y, Vanessa Pereira y, Catarina Lau z, Maria dos Anjos Teixeira z, Marika Bini-Antunes 3 and Margarida Lima 1,* 1 Laboratory of Cytometry, Unit for Hematology Diagnosis, Department of Hematology, Hospital de Santo António (HSA), Centro Hospitalar Universitário do Porto (CHUP), Unidade Multidisciplinar de Investigação Biomédica, Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto (UMIB/ICBAS/UP), 4099-001 Porto Porto, Portugal; [email protected] (S.F.); [email protected] (C.L.); [email protected] (M.d.A.T.) 2 Department of Clinical Pathology, Centro Hospitalar de Vila Nova de Gaia/Espinho (CHVNG/E), 4434-502 Vila Nova de Gaia, Portugal; [email protected] 3 Laboratory of Immunohematology and Blood Donors Unit, Department of Hematology, Hospital de Santo António (HSA), Centro Hospitalar Universitário do Porto (CHUP), Unidade Multidisciplinar de Investigação Biomédica, Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto (UMIB/ICBAS/UP), 4099-001Porto, Portugal; [email protected] * Correspondence: [email protected]; Tel.: + 351-22-20-77-500 These authors contributed equally to this work. y These authors contributed equally to this work. z Received: 10 February 2020; Accepted: 13 March 2020; Published: 16 March 2020 Abstract: Gamma delta T cells (Tc) are divided according to the type of Vδ and Vγ chains they express, with two major γδ Tc subsets being recognized in humans: Vδ2Vγ9 and Vδ1.
  • Targeting Costimulatory Molecules in Autoimmune Disease

    Targeting Costimulatory Molecules in Autoimmune Disease

    Targeting costimulatory molecules in autoimmune disease Natalie M. Edner1, Gianluca Carlesso2, James S. Rush3 and Lucy S.K. Walker1 1Institute of Immunity & Transplantation, Division of Infection & Immunity, University College London, Royal Free Campus, London, UK NW3 2PF 2Early Oncology Discovery, Early Oncology R&D, AstraZeneca, Gaithersburg, MD, USA 3Autoimmunity, Transplantation and Inflammation Disease Area, Novartis Institutes for Biomedical Research, Basel, Switzerland *Correspondence: Professor Lucy S.K. Walker. Institute of Immunity & Transplantation, Division of Infection & Immunity, University College London, Royal Free Campus, London, UK NW3 2PF. Tel: +44 (0)20 7794 0500 ext 22468. Email: [email protected]. 1 Abstract Therapeutic targeting of immune checkpoints has garnered significant attention in the area of cancer immunotherapy, and efforts have focused in particular on the CD28 family members CTLA-4 and PD-1. In autoimmunity, these same pathways can be targeted to opposite effect, to curb the over- exuberant immune response. The CTLA-4 checkpoint serves as an exemplar, whereby CTLA-4 activity is blocked by antibodies in cancer immunotherapy and augmented by the provision of soluble CTLA-4 in autoimmunity. Here we review the targeting of costimulatory molecules in autoimmune disease, focusing in particular on the CD28 family and TNFR family members. We present the state-of-the-art in costimulatory blockade approaches, including rational combinations of immune inhibitory agents, and discuss the future opportunities and challenges in this field. 2 The risk of autoimmune disease is an inescapable consequence of the manner in which the adaptive immune system operates. To ensure effective immunity against a diverse array of unknown pathogens, antigen recognition systems based on random gene rearrangement and mutagenesis have evolved to anticipate the antigenic universe.
  • Targeting and Utilizing Primary Tumors As Live Vaccines: Changing Strategies

    Targeting and Utilizing Primary Tumors As Live Vaccines: Changing Strategies

    Cellular & Molecular Immunology (2012) 9, 20–26 ß 2012 CSI and USTC. All rights reserved 1672-7681/12 $32.00 www.nature.com/cmi REVIEW Targeting and utilizing primary tumors as live vaccines: changing strategies Xuanming Yang, Eric D Mortenson and Yang-Xin Fu Tumor metastases and relapse are the major causes of morbidity and mortality in cancer. Although surgery, chemotherapy and/or radiation therapy can typically control primary tumor growth, metastatic and relapsing tumors are often inaccessible or resistant to these treatments. An adaptive immune response can be generated during these conventional treatments of the primary tumor, and presumably both the primary tumor and secondary metastases share many of the same or similar antigenic characteristics recognized by the immune system. Thus, when established, this response should be able to control metastatic growth and tumor relapse. This review summarizes the mechanisms by which antitumor immune responses are generated, and recent findings supporting the hypothesis that many therapies targeting primary tumors can generate antitumor adaptive immune responses to prevent metastases and tumor relapse. Cellular & Molecular Immunology (2012) 9, 20–26; doi:10.1038/cmi.2011.49; published online 21 November 2011 Keywords: chemotherapy; immunotherapy; metastasis; radiotherapy; tumor vaccine INTRODUCTION tissues.3–5 Thus, overcoming tumor-associated immune-suppressive Conventional treatments such as surgery and chemotherapy are effec- mechanisms to induce potent antitumor immunity is the first step for tive means of eliminating or reducing primary tumor growth, but have effective cancer immunotherapy.5–7 Many mechanisms are involved not proved effective in eradicating metastases. Because metastatic dis- in tumor-associated immune suppression of naive and previously ease may not respond similarly to chemotherapies used in treating the activated T cells.
  • Genetic Defects in B-Cell Development and Their Clinical Consequences H Abolhassani,1,2 N Parvaneh,1 N Rezaei,1 L Hammarström,2 a Aghamohammadi1

    Genetic Defects in B-Cell Development and Their Clinical Consequences H Abolhassani,1,2 N Parvaneh,1 N Rezaei,1 L Hammarström,2 a Aghamohammadi1

    REVIEWS Genetic Defects in B-Cell Development and Their Clinical Consequences H Abolhassani,1,2 N Parvaneh,1 N Rezaei,1 L Hammarström,2 A Aghamohammadi1 1Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran 2Division of Clinical Immunology, Department of Laboratory Medicine, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden n Abstract Expression of selected genes in hematopoietic stem cells has been identified as a regulator of differentiation of B cells in the liver and bone marrow. Moreover, naïve B cells expressing surface immunoglobulin need other types of genes for antigen-dependent development in secondary lymphoid organs. Many advanced molecular mechanisms underlying primary antibody deficiencies in humans have been described. We provide an overview of the mutations in genes known to be involved in B-cell development and their clinical consequences. Key words: Genetic disorder. B-cell development. Primary antibody deficiencies. Clinical phenotypes. n Resumen Se ha identificado la expresión de genes seleccionados en las células pluripotenciales de médula ósea como reguladores de la diferenciación de las células B en el hígado y en médula ósea. Sin embargo, las células B naïve que expresan inmunoglubulinas de superficie, necesitan otros tipos de genes para su desarrollo en los órganos linfoides secundarios dependienteS de antígeno. Se han descrito muchos mecanismos moleculares avanzados que subrayan las inmunodeficiencias en humanos y esta revisión constituye una visión general de la mutación en todos los genes conocidos involucrados en el desarrollo de las células B y sus consecuencias clínicas. Palabras clave: Alteraciones genéticas. Desarrollo de las células B.
  • Iotest CD278 (ICOS)-APC

    Iotest CD278 (ICOS)-APC

    IOTest CD278 (ICOS)-APC PN B36127 – 0.5 mL – Liquid – Clone ISA-3 Analyte Specific Reagent. Analytical and performance characteristics are not established. 2. Hutloff, A., Dittrich, AM., Beier, KC., SPECIFICITY REAGENT CONTENTS Eljaschewitsch, B., Kraft, R., The ICOS molecule (inducible T-cell This antibody is provided in phosphate- Anagnostopoulos, I., Kroczek, RA., costimulator, Inducible Costimulator), also buffered saline, containing 0.1% sodium “ICOS is an inducible T-cell co- known as CD278 antigen (1), belongs to the azide and 2 mg/mL bovine serum albumin. stimulator structurally and functionally CD28 and CTLA-4 cell-surface receptor Concentration: See lot specific Certificate of related to CD28”, 1999, Nature. 21, family and shares 27% and 18% homology Analysis at www.beckmancoulter.com. 397, 263-266. with respectively CD28 and CTLA-4. 3. Haimila, KE., Partanen, JA., The CD278 molecule is a disulfide-linked STATEMENTS OF WARNING 1. This reagent contains 0.1% sodium Holopainen, PM., “Genetic homodimeric T-cell surface glycoprotein of polymorphism of the human ICOS 55-60 kDa whose extracellular region azide. Sodium azide under acid conditions yields hydrazoic acid, an gene”, 2002, Immunogenetics, 53, 12, consists of a single immunoglobulin (Ig) 1028-1032. superfamily V-set domain (2). extremely toxic compound. Azide compounds should be flushed with 4. Shwartz, R.H., “It takes more than two This molecule is encoded by a gene located to tango”, 2001, Nature, 409, 31-32. on the chromosome 2 (2q33) (3). running water while being discarded. These precautions are recommended 5. Sperling, AI., Bluestone, JA., “ICOS The CD278 molecule plays an important role costimulation: It's not just for TH2 cells in cell-cell signaling, immune responses, to avoid deposits in metal piping in which explosive conditions can anymore”, 2001, Nat.